Please login to the form below

Not currently logged in
Email:
Password:

Age-related macular degeneration

This page shows the latest Age-related macular degeneration news and features for those working in and with pharma, biotech and healthcare.

Novartis to pay up to $1.5bn for Gyroscope

Novartis to pay up to $1.5bn for Gyroscope

GA is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss.

Latest news

  • AbbVie signs gene therapy deal in eye care AbbVie signs gene therapy deal in eye care

    AbbVie and REGENXBIO have formed a strategic partnership to develop and commercialise a potential gene therapy for wet age-related macular degeneration (AMD), diabetic retinopathy (DR) and other chronic retinal diseases. ... DR is the leading cause of

  • CHMP recommends eight new medicines for EU approval CHMP recommends eight new medicines for EU approval

    Byoovis is designed for the treatment of wet age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to

  • Novartis and smartpatient launch app experience for wet AMD patients Novartis and smartpatient launch app experience for wet AMD patients

    Wet AMD is the leading cause of severe vision loss and legal blindness in people over the age of 65. ... Novartis and smartpatient have launched a new educational app experience for patients with age-related wet macular degeneration (AMD).

  • Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

    Beovu (brolucizumab) is the first anti-VEGF treatment to demonstrate superior resolution of retinal fluid compared to Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), according to Novartis.

  • Cosentyx, Entresto drive topline growth for Novartis in Q4 Cosentyx, Entresto drive topline growth for Novartis in Q4

    Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and

More from news
Approximately 1 fully matching, plus 123 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    for advanced dry Age-related Macular Degeneration (AMD). ... She became Britain’s youngest hospital leader when she was appointed chief executive of Birmingham Children’s Hospital in 2007 at the age of 32, subsequently helping it win Provider Trust

  • Deal Watch October 2018

    RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    treatments for age-related macular degeneration (AMD).

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD). ... Despite the uncertainty and challenges in our environment, particularly related to Brexit, we need

  • Deal Watch February 2016 Deal Watch February 2016

    company. Avalanche's preclinical and research stage gene therapy programmes are focused on a range of ophthalmic diseases, such as wet age-related macular degeneration, utilising adeno-associated virus (AAV) vectors. ... Onxeo is paying around $1.85m

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Biotech: it's a people business

    From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of ... Because of my mother, I was on the other side

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....